KP Rx

Our goal is to optimize value creation across all stages of our investment journey; from clinical trials and FDA approvals, through market validation and product adoption, to successful entry into capital markets and strategic deals. Driving HealthTech from business plan to business success Our unique strategic ecosystem and team’s active engagement help portfolio companies realize their full potential and achieve large-scale success. By providing unparalleled access to invaluable resources in the form of: Clinical infrastructures KOLs Big data Domain experts Financial backing We help our companies gain an in-depth understanding of clinical workflows and procedures, to ensure product-market fit under challenging health economics, deliver better care for patients and create value to all stake holders. We invest in the right fit We invest in promising mid-to-late stage companies developing innovative platform technologies that will become the gold standard in a broad range of disciplines. The main areas of focus include: Medical devices Diagnostics Digital health Healthcare IT AI and ML We look for highly fundable companies with strong management, broad IP protection and a proven track record of execution, that are poised to benefit from the strategic synergies offered by the ALIVE ecosystem.

Cathay Health is dedicated to investing in companies at the convergence of life sciences, healthcare and technology with positive impact on human health. With a reach spanning key bio and tech hubs around the globe, we help companies scale across borders and access new markets, partners and patients. Our Strategy We back venture- and growth-stage companies with emerging technologies that catalyze groundbreaking advances in healthcare. We fund future leaders in tech-enabled medicine with differentiated approaches and strong intellectual property to personalize care, improve access and lower cost. We invest in Series A to C rounds with the ability to lead or co-invest, and help companies scale across borders. Our Focus AreasLife Science Tools Diagnostics Clinical Trial Innovation New Care Models Novel Devices & Materials Enabling Technologies For Advanced Therapies Why Cathay HealthA global platform catalyzing cross-industry collaboration: Cathay Health is affiliated to Cathay Capital – a global investment platform connecting partners and catalyzing collaborations across Europe, North America and Asia to solve the world’s most pressing challenges. Scaling companies to transform health across borders: Our global network and operating expertise across regions allows us to grow impactful companies that serve patients worldwide. Deep expertise in both healthcare and technology: Our unique expertise allows us to identify investment opportunities with the largest impact on human health and care. Investing & operating at the convergence Our team not only invests – but brings operating experience – at the convergence of life sciences, healthcare and tech. Our expertise uniquely bridges these complementary fields to maximize the potential of our portfolio companies.

InVitro Capital is a venture studio that creates, builds, and exits companies in the AI and B2B space. With a primary focus on Healthcare and SaaS, Invitro has developed a unique recipe to de-risk startup innovation and help aspiring exceptional entrepreneurs identify and capitalize on promising opportunities. At InVitro, we believe that the best startups are built by teams with deep domain expertise and a passion for solving real-world problems. That's why we invest in and partner with entrepreneurs who have a proven track record of success and a vision for the future. We provide our portfolio companies with the operational muscles and support they need to succeed, including: Seed funding. Access to our network of mentors and advisors. Expertise in tech, marketing, sales, and business development. Help with go-to-market strategy. We also have a unique approach to exits. Instead of waiting for a large tech company to come knocking, we actively work with our portfolio companies to develop and execute their own exit strategies. This allows us to maximize returns for our investors and give our entrepreneurs the freedom to pursue their next big idea

Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech and diagnostics, therapeutics and frontier technology.

Founded in 2020, Citta Capital is a venture capital firm based in Palo Alto, California. We prefer to invest in early stage and early growth stage companies in AI/ML, big data, cloud, healthcare technology, IoT, marketplaces, SaaS and enterprise, blockchain, and robotics. Our seasoned investment team has a good mix of extensive startup experiences as entrepreneur and strong operating background as senior executive of global companies. We are committed to be your long-term partners to take on challenges and pursue game-changing ideas.

Earlybird is a venture capital investor focused on European technology innovators. Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources but also strategic support plus access to an international network and capital markets. Earlybird Venture Capital has grown to four autonomous, dedicated and specialized teams, focusing on different geographies and sectors. The Digital West Fund focuses primarily on early stage digital technology opportunities in GSA, Nordics, UK, Benelux, France and Southern Europe, while the Digital East Fund is focused on early stage ICT investment opportunities in Eastern Europe and Turkey, being the leading tech VC in this region. The Health Fund focuses on early and later stage opportunities in digital health, medical devices, diagnostics, enabling technologies and biopharma across Europe. Earlybird UNI-X backs deep tech innovation, including robotics, AI, and mobility, at the earliest stages – tapping into a network of leading European universities. With EUR 2 billion under management, eight IPOs and 30 trade sales, Earlybird is one of the most established and active venture capital firms in Europe. Beyond delivering financial returns, we clearly see our own entrepreneurial responsibility for the environment as well as society and strive to make a positive contribution towards solving the global climate crisis. We are committed to running our own operations in a more eco-sustainable way and offset the residual carbon-footprint while expecting the same from our portfolio companies.